{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T01:30:15Z","timestamp":1768354215698,"version":"3.49.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007184","name":"Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007184","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:p>The federal government and several states have implemented measures to restrict, ban, and increase transparency of promotional payments from pharmaceutical companies to clinicians who prescribe medications. In 2018, New Jersey adopted a novel rule that included a $10 000 restriction on aggregate annual prescriber compensation for promotional speaking, advisory board participation, and consulting arrangements. In this study, we estimated changes associated with the restriction by comparing payments made to physicians in New Jersey to those in a comparator state, Pennsylvania, where no such rule exists. We found that the New Jersey restriction was associated with no significant difference in the proportion of physicians receiving aggregate honoraria and consulting payments above $10 000 annually as compared to physicians in Pennsylvania. Further research is needed to better understand the effect of state policies restricting pharmaceutical industry payments to prescribers.<\/jats:p>","DOI":"10.1093\/haschl\/qxaf254","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T12:38:42Z","timestamp":1767098322000},"source":"Crossref","is-referenced-by-count":0,"title":["Changes in pharmaceutical industry payments to physicians after New Jersey's 2018 restriction"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4700-3407","authenticated-orcid":false,"given":"Neeraj G","family":"Patel","sequence":"first","affiliation":[{"name":"Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3845-3606","authenticated-orcid":false,"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of General Medicine, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph S","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of General Medicine, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Department of Health Policy and Management, Yale School of Public Health , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"15","key":"2026011313042590500_qxaf254-B1","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jama.2024.1989","article-title":"Industry payments to US physicians by specialty and product type","volume":"331","author":"Sayed","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"2026011313042590500_qxaf254-B2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.7326\/m20-5665","article-title":"Are financial payments from the pharmaceutical industry associated with physician prescribing?","volume":"174","author":"Mitchell","year":"2020","journal-title":"Ann Intern Med."},{"key":"2026011313042590500_qxaf254-B3","author":"N.J. Admin. Code Tit. 13, ch. 45J\u2014LIMITATIONS ON AND OBLIGATIONS ASSOCIATED WITH PRESCRIBER ACCEPTANCE OF COMPENSATION FROM PHARMACEUTICAL MANUFACTURERS"},{"key":"2026011313042590500_qxaf254-B4"},{"key":"2026011313042590500_qxaf254-B5","author":"AAMC"},{"key":"2026011313042590500_qxaf254-B6","author":"Habibi"},{"issue":"1","key":"2026011313042590500_qxaf254-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41073-019-0087-1","article-title":"Impact of US industry payment disclosure laws on payments to surgeons: a natural experiment","volume":"5","author":"Rhee","year":"2020","journal-title":"Res Integr Peer Rev."}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxaf254\/66164090\/qxaf254.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/4\/1\/qxaf254\/66164090\/qxaf254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/4\/1\/qxaf254\/66164090\/qxaf254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T18:04:32Z","timestamp":1768327472000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxaf254\/8407378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxaf254","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,30]]},"article-number":"qxaf254"}}